Skip to content

Study · Randomized controlled trial · n = 43 · 2013

5 results

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia.

Lorenz M, Pfeiffer C, Steinsträsser A, Becker RH, Rütten H, Ruus P, Horowitz M

Regulatory peptides9 May 2013Cited by 123 (Europe PMC)

PMID23665027 (opens in a new tab)DOI10.1016/j.regpep.2013.04.001 (opens in a new tab)PepBankPUB-23665027
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, lixisenatide reduced post-breakfast glucose versus placebo (p<0.0001).

    In plain wordsIn patients with diabetes, lixisenatide lowered glucose after breakfast more than placebo.

    Peptide
    Lixisenatide
    Outcome
    DecreasePost-breakfast glucose
    Study

    n = 43

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5-20 μg, increased every fifth day by 2.5 μg · subcutaneous · 28 daysAs given in this study (human).

    Source sentences

    Summary
    With lixisenatide 20 μg QD, there was a reduction in PPG when compared with placebo after breakfast (p<0.0001), lunch (p<0.001) and dinner (p<0.05).
    2 context sentences
    Summary · context
    Data were obtained from a randomized, double-blind, placebo-controlled, parallel-group study with treatment duration of 28 days in patients with T2DM receiving ≤2 oral antidiabetic drugs.
    Summary · context
    Lixisenatide was injected subcutaneously using an ascending dose range (5-20 μg) increased every fifth day in increments of 2.5 μg.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, lixisenatide reduced post-lunch glucose versus placebo (p<0.001).

    In plain wordsIn patients with diabetes, lixisenatide lowered glucose after lunch more than placebo.

    Peptide
    Lixisenatide
    Outcome
    DecreasePost-lunch glucose
    Study

    n = 43

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5-20 μg, increased every fifth day by 2.5 μg · subcutaneous · 28 daysAs given in this study (human).

    Source sentences

    Summary
    With lixisenatide 20 μg QD, there was a reduction in PPG when compared with placebo after breakfast (p<0.0001), lunch (p<0.001) and dinner (p<0.05).
    2 context sentences
    Summary · context
    Data were obtained from a randomized, double-blind, placebo-controlled, parallel-group study with treatment duration of 28 days in patients with T2DM receiving ≤2 oral antidiabetic drugs.
    Summary · context
    Lixisenatide was injected subcutaneously using an ascending dose range (5-20 μg) increased every fifth day in increments of 2.5 μg.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, lixisenatide reduced post-dinner glucose versus placebo (p<0.05).

    In plain wordsIn patients with diabetes, lixisenatide lowered glucose after dinner more than placebo.

    Peptide
    Lixisenatide
    Outcome
    DecreasePost-dinner glucose
    Study

    n = 43

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5-20 μg, increased every fifth day by 2.5 μg · subcutaneous · 28 daysAs given in this study (human).

    Source sentences

    Summary
    With lixisenatide 20 μg QD, there was a reduction in PPG when compared with placebo after breakfast (p<0.0001), lunch (p<0.001) and dinner (p<0.05).
    2 context sentences
    Summary · context
    Data were obtained from a randomized, double-blind, placebo-controlled, parallel-group study with treatment duration of 28 days in patients with T2DM receiving ≤2 oral antidiabetic drugs.
    Summary · context
    Lixisenatide was injected subcutaneously using an ascending dose range (5-20 μg) increased every fifth day in increments of 2.5 μg.
  4. 04HumanNon-randomized trialActivity measurement

    In patients with type 2 diabetes, 50% gastric emptying time increased from baseline with lixisenatide 20 μg QD (mean change 211.5 ± 278.5 min) but not with placebo (-24.1 ± 133.1 min); p<0.01.

    In plain wordsIn patients with diabetes, stomach emptying took longer than at baseline with lixisenatide, but not with placebo.

    Peptide
    Lixisenatide
    Outcome
    IncreaseGastric half-emptying time
    Study

    n = 43

    Comparator
    Baseline
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    5-20 μg, increased every fifth day by 2.5 μg · subcutaneous · 28 daysAs given in this study (human).

    Measurements

    Change from baseline in 50% gastric emptying time (mean)
    211.5 min
    lixisenatide 20 μg QD, SD 278.5 min
    Change from baseline in 50% gastric emptying time (mean)
    −24.1 min
    placebo, SD 133.1 min

    Source sentences

    Summary
    Gastric emptying (50% emptying time) increased substantially from baseline with lixisenatide 20 μg QD, but not with placebo (change from baseline ± SD: -24.1 ± 133.1 min for placebo and 211.5 ± 278.5 min for lixisenatide; p<0.01).
    3 context sentences
    Summary · context
    Gastric emptying of the standardized breakfast was determined by a (13)C-octanoic acid breath test at baseline (Day-1) and at Day 28.
    Summary · context
    Data were obtained from a randomized, double-blind, placebo-controlled, parallel-group study with treatment duration of 28 days in patients with T2DM receiving ≤2 oral antidiabetic drugs.
    Summary · context
    Lixisenatide was injected subcutaneously using an ascending dose range (5-20 μg) increased every fifth day in increments of 2.5 μg.
  5. 05HumanObservational studyMechanism

    In lixisenatide-treated patients with diabetes, post-breakfast glucose area under the curve inversely correlated with gastric emptying (r(2)=0.51, p<0.05).

    In plain wordsIn patients with diabetes receiving lixisenatide, post-breakfast glucose was inversely linked to stomach emptying.

    Peptide
    Lixisenatide
    Outcome
    DecreaseGlucose and gastric-emptying association
    Study

    n = 17

    Comparator
    Gastric emptying
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    5-20 μg, increased every fifth day by 2.5 μg · subcutaneous · 28 daysAs given in this study (human).

    Measurements

    Coefficient of determination (r(2)), post-breakfast PPG AUC vs gastric emptying
    0.51 unitless
    lixisenatide 20 μg QD, n=17

    Source sentences

    Summary
    There was an inverse relationship between PPG area under the curve after breakfast and gastric emptying with lixisenatide 20 μg QD (n=17, r(2)=0.51, p<0.05), but not with placebo.
    2 context sentences
    Summary · context
    Data were obtained from a randomized, double-blind, placebo-controlled, parallel-group study with treatment duration of 28 days in patients with T2DM receiving ≤2 oral antidiabetic drugs.
    Summary · context
    Lixisenatide was injected subcutaneously using an ascending dose range (5-20 μg) increased every fifth day in increments of 2.5 μg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.